Clinical Trial

Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
CDK4/6 and Cyclin D1 are significantly expressed in approximately 80% of esophageal and gastroesophageal junction tumors suggesting that CDK4/6 inhibition may be a successful strategy in these chemotherapy and immunotherapy resistant diseases.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-06-04; most recent amendment 2026-05-21.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-11-05
Trial Details
NCT Number NCT04921904
Lead Sponsor Baylor Research Institute
Conditions Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
Enrollment 8 participants
Start Date 2021-06-11
Primary Completion 2024-12-31 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-02-05